Clene to Present at Upcoming May Conferences
Rhea-AI Summary
Clene (Nasdaq: CLNN) will participate in two investor events in early May 2026: a virtual Emerging Growth Conference presentation on May 6, 2026 at 3:25 p.m. ET and one-on-one meetings at the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel, New York.
Presentation access is available via a webcast link and investor meetings are scheduled as 1x1 sessions.
Positive
- None.
Negative
- None.
Market Reaction – CLNN
Following this news, CLNN has declined 16.25%, reflecting a significant negative market reaction. Our momentum scanner has triggered 22 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $6.78. This price movement has removed approximately $15M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flags the target as moving down while 3 peers (including PAVS and BRLS) move up by roughly 3–8%, indicating stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 04 | Regulatory feedback | Positive | +31.8% | FDA minutes supporting potential accelerated approval NDA pathway for CNM-Au8 in ALS. |
| Mar 12 | Earnings and financing | Positive | +6.1% | Full-year 2025 results, narrowed net loss, and oversubscribed registered direct offering. |
| Feb 24 | Pipeline catalysts update | Positive | +9.8% | Outlined 2026 CNM-Au8 catalysts, including accelerated NDA plans and Phase 3 RESTORE-ALS trial. |
| Feb 19 | Investor conference | Neutral | +4.7% | Announcement of a virtual corporate update at the Emerging Growth Conference. |
| Jan 16 | Investor conference | Neutral | -1.2% | Plan to present a corporate update at the January Emerging Growth Conference. |
Recent price reactions have generally aligned with positive regulatory and financing milestones, with strong upside moves on ALS regulatory updates and more modest reactions to conference appearances.
Over the last few months, Clene has reported several key developments. On May 4, 2026, the FDA indicated Clene’s data may support an accelerated approval NDA for CNM-Au8 in ALS, with an NDA targeted for Q3 2026 and a Phase 3 study in Q1 2027, prompting a 31.76% move. Earlier, full-year 2025 results and financing on March 12, 2026 coincided with a 6.09% gain, while a February stockholder letter outlining 2026 catalysts saw a 9.8% rise. Prior conference announcements produced smaller, mixed reactions.
Regulatory & Risk Context
An effective S-3 shelf filed on September 5, 2025 covers 491,496 shares of common stock for resale by existing holders tied to senior secured convertible notes. The company receives no proceeds from these resales, having already obtained cash from the note issuances.
Market Pulse Summary
This announcement highlights Clene’s participation in May investor conferences, offering additional exposure for its late-stage neurodegeneration programs, including ALS and MS. It follows recent FDA feedback supporting a potential accelerated approval NDA for CNM-Au8 and earlier financing transactions. Investors may monitor how upcoming presentations reinforce the regulatory timeline, funding runway, and clinical strategy laid out in prior updates, while considering existing resale capacity tied to convertible note financings.
Key Terms
amyotrophic lateral sclerosis medical
multiple sclerosis medical
AI-generated analysis. Not financial advice.
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May.
Emerging Growth Conference
Date: May 6, 2026
Time of Presentation: 3:25 p.m. ET
Format: Virtual Presentation
Presentation Link: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=clnn
D. Boral Capital Global Conference
Date: May 7, 2026
Location: The Plaza Hotel, New York, New York
Format: 1x1 meetings
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; (617) 283-2856
Media Contact: Caroline Wagner, Forbes Tate Partners; CWagner@forbes-tate.com; (267) 294-6563
